Market revenue in 2022 | USD 540.8 million |
Market revenue in 2030 | USD 1,206.3 million |
Growth rate | 10.5% (CAGR from 2022 to 2030) |
Largest segment | Sickle cell disease |
Fastest growing segment | Sickle cell disease |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Thalassemia, Sickle cell disease, Other Hb Variants |
Key market players worldwide | Sangamo Therapeutics Inc, Global Blood Therapeutics, Bluebird bio Inc, Emmaus Life Sciences Inc, Pfizer Inc, Novartis AG ADR, Prolong Pharmaceuticals, Bioverativ, Gamida Cell, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemoglobinopathies market will help companies and investors design strategic landscapes.
Sickle cell disease was the largest segment with a revenue share of 59.28% in 2022. Horizon Databook has segmented the Japan hemoglobinopathies market based on thalassemia, sickle cell disease, other hb variants covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing focus on the development of new therapies for the treatment of hemoglobinopathies is expected to drive the growth of the market in Japan. According to a 2017 study conducted by University of New South Wales (UNSW) in partnership with RIKEN BioResource Center and Japanese Red Cross Society, a benign genetic mutation called British-198 mutation was introduced in human cells to facilitate fetal hemoglobin production.
Fetal hemoglobin can help in compensating the lack of normal adult hemoglobin, making the disease milder in patients affected by it. Better access to healthcare in the country is also expected to improve screening and treatment for SCD & thalassemia. The recent SARS-CoV-2 pandemic is not expected to impact the supply chain of SCD drugs.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan hemoglobinopathies market , including forecasts for subscribers. This country databook contains high-level insights into Japan hemoglobinopathies market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account